Description
Winstrol Water is the aqueous microcrystal suspension form of Stanozolol. The substance itself is identical with oral or oily Stanozolol forms, only the carrier medium is water with fine-distributed crystals instead of oil. This formulation was the original clinical form (Winstrol Depot from Winthrop Laboratories) since the 1960s.
Per study reports pharmacology remains identical to all Stanozolol forms: DHT derivative with pyrazole ring, no aromatization, strong SHBG lowering, dry cutting profile.
The aqueous suspension has two properties distinguishing it from the oily form: first, faster flood-in due to better water diffusion from the injection depot. Second, substantially higher post-injection inflammation (PIP) - microcrystals mechanically irritate the tissue.
Pharmacokinetically the aqueous form has a half-life of about 24 hours. Daily injections required. The fast action onset makes Winstrol Water attractive in pre-contest research setups where acute effects matter.
Known effects: same Stanozolol effects as under oral or oily forms (HDL drop, joint dryness, ALT/AST elevation) plus the microcrystal-related injection-site reactions. Some customers report painful nodules and inflammatory reactions lasting several days.
In recreational research practice Winstrol Water has become rarer since Stanozolol Oil became available as a more practical alternative. Classical users stick with the water form for the acute action characteristic.
Stanozolol is on the WADA banned list.
You can order Winstrol Water as an aqueous injection suspension in 10-pack at 100mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Winstrol Water shares the full Stanozolol risk profile - the 17-alpha-methyl group makes the substance hepatotoxic, and the aqueous microcrystal suspension additionally brings a pronounced injection-site burden.
Documented in studies and the application literature:
- Hepatotoxicity: the 17-alpha-methyl group acts systemically regardless of the carrier medium. ALT/AST elevations are documented as under all Stanozolol forms.
- Post-injection inflammation: the microcrystals mechanically irritate the tissue. User reports describe painful nodules and inflammatory reactions that can last several days.
- No aromatization: Stanozolol does not aromatize and strongly lowers SHBG. The literature describes a dry profile and pronounced joint dryness.
- Lipid profile and endogenous production: a marked HDL drop and an HPG suppression with reduced endogenous testosterone production are documented.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Contrasting effects of testosterone and stanozolol on serum lipoprotein levels - JAMA 1989, Thompson et al: classical study on HDL drop under stanozolol.
- Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema - Journal of Allergy and Clinical Immunology 1980, Sheffer et al: classical clinical study on the stanozolol indication.
- Preoperative stanozolol therapy in patients with hereditary angioedema - Journal of Allergy and Clinical Immunology 1982, Stiller et al: preoperative application study.
- Response of human skeletal muscle to the anabolic steroid stanozolol - BMJ 1988, Kuipers et al: effects on muscle protein metabolism.
- Hereditary angioedema: safety of long-term stanozolol therapy - Journal of Allergy and Clinical Immunology 2007, Sloane et al: long-term safety data on stanozolol.
